公开(公告)号：US20190000829A1

公开(公告)日：2019-01-03

申请号：US15748980

申请日：2016-08-17

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Junji Matsui ,  Masahiro Matsuki ,  Akihiko Tsuruoka ,  Toshiyuki Tamai ,  Ryo Nakajima ,  Takuya Suzuki

IPC: A61K31/47 ,  A61P35/00 ,  A61K31/095

Abstract: A therapeutic agent for biliary tract cancer comprising 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide or a pharmacologically acceptable salt thereof is provided.

公开(公告)号：US12036204B2

公开(公告)日：2024-07-16

申请号：US17563162

申请日：2021-12-28

Applicant: Eisai R&D Management Co., Ltd. ,  Ono Pharmaceutical Co., Ltd.

Inventor： Taro Semba ,  Yasuhiro Funahashi ,  Takuya Suzuki

IPC: A61K31/357 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/357 ,  A61K39/3955 ,  A61P35/00

Abstract: A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.

公开(公告)号：US20220117933A1

公开(公告)日：2022-04-21

申请号：US17563162

申请日：2021-12-28

Applicant: Eisai R&D Management Co., Ltd. ,  Ono Pharmaceutical Co., Ltd.

Inventor： Taro Semba ,  Yasuhiro Funahashi ,  Takuya Suzuki

IPC: A61K31/357 ,  A61K39/395 ,  A61P35/00

Abstract: A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.